

## CLAIMS

1. A method for evaluating an effect of an agent to be tested on skin, using a transgenic mouse to which an interleukin-18 gene under control of a keratinocyte promoter is introduced,  
5 wherein the following (A) and/or (B) are used as an evaluation indicator.
  - (A) spontaneous dermatitis
  - (B) dermal inflammation at a time of the first administration of a phlogogenous material
- 10 2. The evaluation method according to claim 1, wherein the spontaneous dermatitis reaches its peak on the 8<sup>th</sup> to 12<sup>th</sup> day after birth.
- 15 3. The evaluation method according to claim 1, wherein the object of the evaluation is to screen an agent for preventing / treating autoimmune dermatitis.
4. The evaluation method according to claim 2, wherein the object of the evaluation is to screen an agent for preventing / treating autoimmune dermatitis.
- 20 5. A method for evaluating an effect of an agent to be tested on alopecia, using a transgenic mouse to which an interleukin-18 gene under control of a keratinocyte promoter is introduced.
- 25 6. The evaluation method according to claim 5, wherein the object of the evaluation is to screen an agent for preventing or treating alopecia.
7. An agent for preventing or treating dermatitis and/or alopecia, comprising a

substance that suppresses a cell having an NK1.1 antigen.

8. The agent for preventing or treating dermatitis and/or alopecia according to  
claim 7, wherein the substance that suppresses a cell having an NK1.1 antigen is an  
5 antibody against a cell having an NK1.1 antigen.

9. The agent for preventing or treating dermatitis and/or alopecia according to  
claim 8, wherein the antibody against a cell having an NK1.1 antigen is an antibody  
identifying an asialo GM1 antigen or antibody identifying an NK1.1 antigen.

10

10. A transgenic mouse used to evaluate an effect of an agent to be tested on  
alopecia, to which an interleukin-18 gene under control of a keratinocyte promoter  
is introduced.

15 11. The transgenic mouse according to claim 10, wherein the object of the  
evaluation is to screen an agent for preventing or treating alopecia.